科研動態(tài)

為評價重組禽流感病毒（H5+H7）三價滅活疫苗（H5N1 Re-11株+Re-12株，H7N9 H7 Re-2株）免疫雞群的臨床應(yīng)用效果及當(dāng)前禽流感免疫程序的合理性，對河南省使用重組禽流感病毒（H5+H7）三價滅活疫苗免疫的940個存欄500只以上的養(yǎng)雞場開展臨床應(yīng)用效果調(diào)查，并抽取328個場開展免疫抗體檢測。結(jié)果顯示：免疫后1周內(nèi)出現(xiàn)不良反應(yīng)的養(yǎng)雞場190個，占20.21%（190/940）；發(fā)病的養(yǎng)雞場140個，占14.89%（140/940）；出現(xiàn)死亡的養(yǎng)雞場51個，占5.43%（51/940）。免疫后1周內(nèi)出現(xiàn)不良反應(yīng)的雞只占0.11%，發(fā)病的占0.09%，死亡的占0.04%。血清樣品的血凝（HA）和血凝抑制（HI）試驗結(jié)果顯示：H5亞型Re-11株場群合格率為97.56%，免疫抗體陽性率為94.20%；H5亞型Re-12株場群合格率為96.34%，免疫抗體陽性率為92.70%；H7亞型Re-2株場群合格率為98.17%，免疫抗體陽性率為94.67%。結(jié)果表明：重組禽流感病毒（H5+H7）三價滅活疫苗的雞群免疫效果較好，免疫后的臨床不良反應(yīng)率極低。但在免疫過程中，應(yīng)盡量消除影響疫苗臨床效果的不利因素，定期開展免疫效果監(jiān)測，及時調(diào)整免疫程序。本研究為全國高致病性禽流感疫苗的應(yīng)用提供了參考。

Evaluation on the Clinical Application Effect of Recombinant Avian Influenza Virus（H5+H7）Trivalent Inactivated Vaccines in Chickens

In order to evaluate the clinical application effect of recombinant avian influenza virus（H5+H7）trivalent inactivated vaccines（H5N1 Re-11+Re-12 strain and H7N9 H7 Re-2 strain）in chickens and the rationality of current vaccination program，940 farms with more than 500 chickens were investigated in Henan Province，in which，328 farms were selected for detection of immune antibody. It was found that，within one week after vaccination，some adverse reactions revealed in 190 farms，accounting for 20.21%（190/940）；avian influenza outbreaks in 140 farms were detected，accounting for 14.89%（140/940）；and dead cases were found in 51 farms，accounting for 5.43%（51/940）. The proportions of chickens with adverse reactions，being infected and dead were 0.11%，0.09% and 0.04%，respectively. It was found that，by hemagglutination（HA）and hemagglutination inhibition（HI）test for serum samples，the farm/flock qualified rates of H5 Re-11，H5 Re-12 and H7 Re-2 strain were 97.56%，96.34% and 98.17%，respectively，and their positive rates of immune antibodies were 94.20%，92.70% and 94.67%，respectively. It was concluded that the recombinant avian influenza virus（H5+H7）trivalent inactivated vaccine could receive good effect in chickens，with lower level of adverse reaction. However，any adverse factors therefrom should be eliminated to the greatest extent during the process of vaccination，which should be monitored regularly，and the vaccination program should also be timely adjusted. Some references were provided for the application of vaccines against highly pathogenic avian influenza virus in China.

全文下載鏈接：https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDAUTO&filename=ZGDW202011022&v=Bh8a8ZT44%25mmd2BViTsUIpnMUhMdfl8JdNVN4nOcJGcWypRTOzA9syj9XPAWc4KBTGMQp